Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guard-01 efbemalenograstim alfa primary prophylaxis during concurrent chemoradiotherapy
ChiCTR2300077504Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of efbemalenograstim alfa in neutropenia (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Incidence of grade 3 or higher neutropenia during treatment. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
efbemalenograstim alfa
03
Conditions
neutropenia
Beyond the preview
Go deeper on ChiCTR2300077504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077504.